Sponsor Visits and Monitoring

Slides:



Advertisements
Similar presentations
CMRSC Division of Hematology/Oncology
Advertisements

Investigator Responsibilities in Clinical Research
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
M ODULE F: P RE - STUDY A SSESSMENT V ISIT Denise Thwing 14 Apr Version: Final 14-Apr-2010.
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
Research Coordination Guidance The Committees on Human Research Serving University of Vermont & Fletcher Allen Health Care
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
A Blueprint For Clinical Research: Standard Operating Procedures
MONITORING DIFFERENT TYPES OF TRIALS. BY OGUNDOKUN OLUSEGUN BIOMEDICAL SCIENTIST / CLINICAL RESEARCH PROFESSIONAL BMLS (LAUTECH), PGD (Clin. Research.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Developed by Klinikos; Roy Fraser (2012) Investigator Study File
John Naim, PhD Director Clinical Trials Research Unit
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Stanley Estime, MSCI December 9, 2014 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Monitoring and Special Considerations for Multi-Center Trials
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Feldman 20 February Clinical Trials Design Martha A. Feldman, RAC Drug & Device Development Co., Inc. P.O. Box 3515 Redmond, WA USA
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
6/1/09.
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
STUDY CLOSE OUT KEMRI-Wellcome Trust Research Programme Version: 4-Nov-2008.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
The Bartter Research Unit (BRU) as a Vehicle to Support Research at the South Texas Veterans Health Care System March 2009 Research Study Members Training.
Study Closure Process Entropy is not a method Rachel Sheppard Regulatory Director, OCRSS.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Getting a study done at Jefferson:. Startup Activities: Image courtesy of CITI Program Clinical Research Coordinator course.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Site Monitoring Shirley Frederiksen Donna Harsh.
Stanley Estime, MSCI October 19, 2015 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Investigational Devices and Humanitarian Use Devices June 2007.
How to Start An Industry Sponsored Clinical Trial
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
Lifespan GOOD CLINICAL PRACTICE Record Management GCP May 2005.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Supervisory Responsibilities of Clinical Investigators
Remote Site Initiation Visits
PRCSG Training Webinar: Budget for Industry Sponsored Studies
The Role and Responsibilities of the Clinical Research Coordinator
Responsibilities of Sponsor, Investigator and Monitor
Study Feasibility and Start-up
MAINTAINING THE INVESTIGATOR’S SITE FILE
What is a Data and Safety Monitoring Plan and how do I get one?
Alyssa Speier, MS, CIP November 13, 2013
Elements of an Organized Regulatory Binder
Getting a Study Done at Jefferson:
MAINTAINING THE INVESTIGATOR’S STUDY FILE
TRTO (Translational Research Trials Office)
Monitoring, Auditing and Compliance
Good clinical practice
Presentation transcript:

Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute

Monitoring Monitoring is a very important aspect of a trial. The monitor is the main communication between the sponsor and the Investigator Monitoring is the act of overseeing the progress of a clinical trial and ensuring that it is conducted in accordance with the protocol, SOPs, GCP, and any other regulatory requirements

Types of Monitoring Visits The most common types of site visits for industry-sponsored studies are: Site Assessment (Pre-Study) Visit Site Initiation Visit Interim Monitoring Visit Close Out Site Visit

Site Assessment Visit This visit is conducted to evaluate a site’s and investigator’s resources and capabilities to conduct a study in terms of site infrastructure, adequacy and availability of the site facilities for study conduct

What are they looking for at Site Evaluation Visit? Investigator Qualifications Up to date CV Specialty Previous experience in conducting a trial Adequate resources Sufficient time Adequate staffing Population

What are they looking for at Site Evaluation Visit? Adequate Facilities Exam Rooms Pharmacy/Study Drug Storage area Laboratory or specimen processing area Special testing areas (x-rays, MRIs, CT scans, etc.…) Record keeping facilities

What are they looking for at Site Evaluation Visit? Protocol review and discussion Study objectives Inclusion/exclusion criteria Study procedures/tests Schedule of assessments Competing trials

Site Initiation Visit The Site Initiation Visit is planned to provide study-specific information to investigators and staff prior to study start-up and to reassess resources and capabilities of the site to conduct the research study The monitor will also discuss with the staff about research obligations as per the GCP. The monitor provides necessary guidance to the site to help the site be successful

What happens at the Site Initiation Visit? Review of Investigator responsibilities Protocol Overview Discussion of General Study Procedures Safety: Definitions, Collection, and Reporting of AE/SAE Data Collection/Source Documentation Investigational Product Specimen Processing Clinical Monitoring Plan Regulatory Documents Review Tour of Facility Review of any action items

QUESTIONS?

Interim Monitoring Visit Routine or Interim Monitoring visits are basically any visit that occurs after the site is initiated and up until the site is closed out The objective of these visits is to assess the progress of the trial in terms of accuracy, completeness and verification of reported trial data

What information is reviewed during the visit? Informed Consent Documents Study subjects research records Source documentation Regulatory binders Occurrence and reporting of adverse events and protocol deviations Action items from previous monitoring visit

Other Comments about monitor visits Monitors usually come out an average of every three months for a one day visit. This may vary depending on the study and enrollment It is expected that your monitor will come out within 2 weeks of you enrolling your first patient You must provide for your monitor a desk or other ample space in a fairly quiet area with access to a telephone and an internet connection They also will want to meet with the PI for a few minutes to discuss the study and any other issues or concerns

QUESTIONS?

Close Out Site Visit The close out visit occurs after study completion or site withdrawal In general, three activities are required to “officially” close out a site The monitor conducts a close-out visit and signs the monitoring log The Principal investigator submits a final report to the IRB stating that the site is closed The sponsor sends a letter stating that the site is closed

What happens at a Close out visit? The monitor conducts a final data review/collection of all outstanding data Study drug is returned or destroyed on site A final review of the regulatory binder is done And, if applicable, verification that all blood/biological samples have been submitted Return or destruction of all unused forms/CRFs Review and collection of Delegation of Authority forms Collection of IRB closure report/letter

QUESTIONS?

Thank You!